Why This Matters
GLP-1 drugs are already known to do far more than regulate blood glucose and reduce body weight. Patients taking semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have consistently reported reductions in cravings for alcohol, tobacco, and food. Clinical trials have shown reductions in alcohol use disorder symptoms. A growing body of evidence points to GLP-1 receptors distributed throughout the brain in regions governing reward processing, craving, and impulse control.
A June 2026 study from Rutgers University is the first peer-reviewed research to extend that observation into a different domain: violent behavior. The findings are striking, the caveats are significant, and the question the study raises is now being taken seriously by clinicians and criminologists in ways that will require much stronger evidence to answer definitively.
What We Know So Far
The study, led by Dr. Daniel C. Semenza, director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, and co-authored by Christopher Thomas, an assistant professor at Rutgers University-Camden, was published June 17, 2026, in Criminology, the flagship peer-reviewed journal of the American Society of Criminology.
Researchers analyzed data from a 2025 nationally representative survey of 7,521 U.S. adults. The primary analysis focused on 821 individuals who had ever used a GLP-1 medication, comparing current users against former users. They examined whether GLP-1 medication status changed the relationship between violent behavior, impulsivity, and alcohol use.
Two central findings emerged. Among current GLP-1 users, the well-established link between high impulsivity and violent behavior was approximately 62% weaker than among former users. The connection between alcohol use and violent behavior was approximately 52% weaker among current users, though this second finding was less consistent across the study's sensitivity analyses.
Violent behavior was measured using a validated self-reporting offending scale assessing acts including fighting, assault, and robbery.
Where the Research Stands — and Its Significant Limits
The study's design is cross-sectional and observational. Participants reported their own behavior and their own drug use. The research cannot account for whether the people who continue using GLP-1 drugs are systematically different in personality, impulse control, or circumstances from those who stopped, which could produce the apparent association without any pharmacological mechanism.
The former-user comparison group is a methodological limitation that the authors acknowledged. People stop GLP-1 medications for many reasons, including side effects, cost, or clinical failure. If people who respond poorly to the drug (for any reason) are more likely to stop, the comparison group may already differ from current users in ways that correlate with violence risk, independent of the medication itself.
Self-reported violent behavior also tends to undercount actual violence. The finding may not apply equally across GLP-1 drug types, doses, or populations, and no dosing or medication-specific data were presented.
What Doctors and Experts Say
Christopher Thomas offered a mechanistic framing for the finding in the Rutgers press release: "Our findings are consistent with these medications working like cognitive behavioral therapy, weakening the path from impulse to action rather than eliminating impulsivity itself."
The analogy is instructive. Cognitive behavioral therapy does not remove impulsive thoughts; it helps people not act on them. If GLP-1 drugs are producing a similar effect on the neural circuits involved in translating impulse into action, that would be consistent with the known distribution of GLP-1 receptors in brain regions including the prefrontal cortex, hypothalamus, and the mesolimbic dopamine system governing reward and craving.
Dr. Betul Hatipoglu, a professor of medicine at Case Western Reserve University School of Medicine who was not involved in the study, commented to Healthline on the finding: "The strongest signal was the interaction between GLP-1 use and impulsivity, suggesting that the usual association between impulsivity and violent behavior was substantially attenuated among current GLP-1 users. This study is interesting, but we will need larger, longitudinal, and ideally experimental studies to understand whether this association reflects a true pharmacological effect."
What the Evidence Shows and What It Does Not
This is a single cross-sectional observational study using self-reported data. It identifies a statistical association; it does not establish that GLP-1 drugs cause reductions in violent behavior. The study was not designed or powered to make causal claims, and the authors did not make them.
The finding is consistent with the broader scientific literature on GLP-1 effects on the brain. But consistency with a hypothesis is not the same as confirming it.
MedicalDaily Evidence Check
- Study type: Cross-sectional observational study using self-reported survey data
- Institution: Rutgers University (New Jersey Gun Violence Research Center, School of Public Health)
- Published in: Criminology, June 17, 2026
- Participants: 821 GLP-1 users within a nationally representative survey of 7,521 adults
- What it found: The impulsivity-violence link was approximately 62% weaker among current GLP-1 users vs. former users; the alcohol-violence link was approximately 52% weaker (less consistent across sensitivity analyses)
- What it did not prove: That GLP-1 drugs cause reductions in violent behavior; causal direction is not established; self-reported data have known limitations
-
What readers should know: This finding adds to an important and growing body of evidence about GLP-1 effects on the brain, but it is far too preliminary to influence prescribing decisions related to violence or impulsivity
Who Faces the Greatest Risk — or May Benefit Most from Future Research?
People with conditions that have both established GLP-1 benefit and overlap with impulsivity include alcohol use disorder, binge eating disorder, and some presentations of attention-deficit/hyperactivity disorder. None of these are currently approved indications for GLP-1 medications, and this study does not change that.
The populations who currently qualify for GLP-1 prescriptions include adults with obesity or overweight with at least one weight-related comorbidity, and adults with type 2 diabetes. Approved indications also include cardiovascular risk reduction in adults with established heart disease and type 2 diabetes, for some agents.
Symptoms and Warning Signs to Watch For
This article covers research on the behavioral effects of GLP-1 drugs and does not pertain to any specific disease presentation. Readers interested in whether a GLP-1 medication is appropriate for their situation should consult a licensed clinician familiar with their complete medical and psychiatric history.
People taking GLP-1 medications who experience significant mood changes, increased irritability, or behavioral changes should report them to their prescribing clinician, as these effects would be relevant to ongoing safety monitoring.
What You Can Do Now
- If you are currently taking a GLP-1 medication for an approved indication, continue treatment as prescribed and discuss any behavioral or mood changes with your physician at your next appointment.
- Do not seek a GLP-1 prescription for impulsivity, violence reduction, or mood management based on this single observational study. No approved indication for these uses exists, and the evidence does not support them.
-
If you are concerned about impulsive behavior, alcohol use, or violence risk in yourself or someone you care for, speak with a mental health professional or contact
SAMHSA's National Helpline
at 1-800-662-4357 for free and confidential guidance.
Cost and Access: What Patients Should Know
GLP-1 medications are expensive, and coverage varies. The Medicare GLP-1 Bridge Program, which launched July 1, 2026, provides access at $50 per month for eligible Medicare Part D beneficiaries with obesity who meet clinical criteria. Commercial insurance coverage for obesity indications varies by plan. Self-pay options exist through manufacturers' patient assistance programs and newer oral formulations.
Access for behavioral health indications is not applicable at this time because no such indication is approved.
What Happens Next
The study authors call for larger, longitudinal, and ideally experimental research designs to test whether the association they found reflects a true pharmacological effect or a selection artifact. A randomized controlled trial in which GLP-1 drugs are assigned to people with documented impulsivity problems and followed for behavioral outcomes would be the gold standard. No such trial has been announced.
The finding adds to a broader scientific conversation about GLP-1 effects on the central nervous system that is producing research across multiple domains, including addiction, compulsive behavior, depression, and now violent impulsivity. That conversation is gaining traction in clinical medicine and is worth following as higher-quality evidence accumulates.
The Bottom Line
A Rutgers criminology study published in June 2026 found that among current GLP-1 users, the well-established statistical link between impulsivity and violent behavior was approximately 62% weaker than among former users. The study is observational, cross-sectional, and based on self-reported behavior, and it cannot establish that GLP-1 drugs cause this effect. But the finding is consistent with growing evidence that GLP-1 receptors in the brain affect reward and impulse circuitry in ways that extend well beyond glucose regulation. Larger, more rigorous research is needed before any clinical guidance on this question can be established.
